A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

ID#: NCT05201781

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Study Phase: Phase 4

Recruitment Status: Recruiting

Start Date: March 09, 2022

End Date: October 30, 2037

Contact Information:
Study Contact
844-434-4210
Summary: The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.
Eligibility:

Inclusion Criteria:

- Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study

- Participants who have provided informed consent for this study
Find a Clinical Trial Find Cancer Clinical Trials